Neuropeptide Y and neurovascular control in skeletal muscle and skin.

Neuropeptide Y (NPY) is a ubiquitous peptide with multiple effects on energy metabolism, reproduction, neurogenesis, and emotion. In addition, NPY is an important sympathetic neurotransmitter involved in neurovascular regulation. Although early studies suggested that the vasoactive effects of NPY were limited to periods of high stress, there is growing evidence for the involvement of NPY on baseline vasomotor tone and sympathetically evoked vasoconstriction in vivo in both skeletal muscle and the cutaneous circulation. In Sprague-Dawley rat skeletal muscle, Y(1)-receptor activation appears to play an important role in the regulation of basal vascular conductance, and this effect is similar in magnitude to the alpha(1)-receptor contribution. Furthermore, under baseline conditions, agonist and receptor-based mechanisms for Y(1)-receptor-dependent control of vascular conductance in skeletal muscle are greater in male than female rats. In skin, there is Y(1)-receptor-mediated vasoconstriction during whole body, but not local, cooling. As with the NPY system in muscle, this neural effect in skin differs between males and females and in addition, declines with aging. Intriguingly, skin vasodilation to local heating also requires NPY and is currently thought to be acting via a nitric oxide pathway. These studies are establishing further interest in the role of NPY as an important vasoactive agent in muscle and skin, adding to the complexity of neurovascular regulation in these tissues. In this review, we focus on the role of NPY on baseline vasomotor tone in skeletal muscle and skin and how NPY modulates vasomotor tone in response to stress, with the aim of compiling what is currently known, while highlighting some of the more pertinent questions yet to be answered.

[1]  W. Haefeli,et al.  Subconstrictor Doses of Neuropeptide Y Potentiate α1-Adrenergic Venoconstriction In Vivo , 1996 .

[2]  D. Larhammar,et al.  Cloning and functional expression of a human neuropeptide Y/peptide YY receptor of the Y1 type. , 1992, The Journal of biological chemistry.

[3]  R. Malmström,et al.  Effects of the neuropeptide Y Y2 receptor antagonist BIIE0246 on sympathetic transmitter release in the pig in vivo , 2002, Naunyn-Schmiedeberg's Archives of Pharmacology.

[4]  J. Pernow,et al.  Evidence for two neuropeptide Y receptors mediating vasoconstriction. , 1991, European journal of pharmacology.

[5]  G. Brengelmann,et al.  Temperature Regulation in the Neutral Zone , 1997, Annals of the New York Academy of Sciences.

[6]  Z. Żukowska-Grójec,et al.  Cardiovascular, neuropeptide Y, and adrenergic responses in stress are sexually differentiated , 1991, Physiology & Behavior.

[7]  J E Faber,et al.  Trophic Effect of Norepinephrine on Arterial Intima-Media and Adventitia Is Augmented by Injury and Mediated by Different &agr;1-Adrenoceptor Subtypes , 2001, Circulation research.

[8]  J. Johnson,et al.  Selective abolition of adrenergic vasoconstrictor responses in skin by local iontophoresis of bretylium. , 1989, The American journal of physiology.

[9]  John M. Johnson,et al.  Cardiovascular Adjustments to Heat Stress , 2011 .

[10]  J. W. Mcroberts,et al.  Carotid artery loop method of blood pressure measurement in the dog. , 1971, Journal of applied physiology.

[11]  Z. Żukowska-Grójec,et al.  Endogenous neuropeptide Y mediates vasoconstriction during endotoxic and hemorrhagic shock , 1998, Regulatory Peptides.

[12]  L. Grundemar Multiple receptors and multiple actions , 1997 .

[13]  M. Heath Neuropeptide Y and Y1-receptor agonists increase blood flow through arteriovenous anastomoses in rat tail. , 1998, Journal of applied physiology.

[14]  C. Wahlestedt,et al.  Evidence for different pre- and post-junctional receptors for neuropeptide Y and related peptides , 1986, Regulatory Peptides.

[15]  N. Holliday,et al.  Neuropeptide Y and Related Peptides , 2004, Handbook of Experimental Pharmacology.

[16]  L. Edvinsson,et al.  Neuropeptide Y potentiates noradrenaline-evoked vasoconstriction by an intracellular calcium-dependent mechanism. , 1993, Journal of the autonomic nervous system.

[17]  C. Wahlestedt,et al.  Neuropeptide Y potentiates the effect of various vasoconstrictor agents on rabbit blood vessels , 1984, British journal of pharmacology.

[18]  E. Ravussin,et al.  Gender differences in muscle sympathetic nerve activity: effect of body fat distribution. , 1996, The American journal of physiology.

[19]  J. Lundberg,et al.  Inhibition of sympathetic vasoconstriction in pigs in vivo by the neuropeptide Y‐Y1 receptor antagonist BIBP 3226 , 1995, British journal of pharmacology.

[20]  John M. Johnson,et al.  Evidence for a Role for Vasoactive Intestinal Peptide in Active Vasodilatation in the Cutaneous Vasculature of Humans , 2003, The Journal of physiology.

[21]  J. Faber,et al.  Alpha(1)-adrenoceptor stimulation directly induces growth of vascular wall in vivo. , 2002, American journal of physiology. Heart and circulatory physiology.

[22]  R. Marshall,et al.  Blood Pressure during Supine Exercise in Idiopathic Orthostatic Hypotension , 1961, Circulation.

[23]  K. Hagbarth,et al.  Regional similarities and differences in thermoregulatory vaso‐ and sudomotor tone. , 1980, The Journal of physiology.

[24]  P. Clifford,et al.  Exercise attenuates α-adrenergic-receptor responsiveness in skeletal muscle vasculature , 2001 .

[25]  P. Clifford,et al.  Neuropeptide Y1 receptor vasoconstriction in exercising canine skeletal muscles. , 2005, Journal of applied physiology.

[26]  C. Wahlestedt,et al.  The Biology of Neuropeptide Y and Related Peptides , 1993, Contemporary Neuroscience.

[27]  C. Y. Chen,et al.  Onset of exercise increases lumbar sympathetic nerve activity in rats. , 1996, Medicine and science in sports and exercise.

[28]  H. Monyer,et al.  Molecular cloning of a novel G protein‐coupled receptor that may belong to the neuropeptide receptor family , 1990, FEBS letters.

[29]  J. Shine,et al.  Cloned human neuropeptide Y receptor couples to two different second messenger systems. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[30]  D. McCloskey,et al.  Neuropeptide Y and control of vascular resistance in skeletal muscle , 1988, Regulatory Peptides.

[31]  D. A. Williams,et al.  Physiologically derived critical evaporative coefficients for protective clothing ensembles. , 1987, Journal of applied physiology.

[32]  P. Clifford,et al.  Sympathetic vasoconstriction in active skeletal muscles during dynamic exercise. , 1997, Journal of applied physiology.

[33]  R. Klabunde Attenuation of reactive and active hyperemia by sympathetic stimulation in dog gracilis muscle. , 1986, The American journal of physiology.

[34]  G. Burnstock,et al.  ATP mediates coronary vasoconstriction via P2x-purinoceptors and coronary vasodilatation via P2y-purinoceptors in the isolated perfused rat heart. , 1987, European journal of pharmacology.

[35]  Z. Żukowska-Grójec Neuropeptide Y , 1995, Annals of the New York Academy of Sciences.

[36]  T. Hökfelt,et al.  Neuropeptide Y (NPY)-like immunoreactivity in peripheral noradrenergic neurons and effects of NPY on sympathetic function. , 1982, Acta physiologica Scandinavica.

[37]  J. Marshall,et al.  Contribution of α2-adrenoceptors and Y1 neuropeptide Y receptors to the blunting of sympathetic vasoconstriction induced by systemic hypoxia in the rat , 2007, The Journal of physiology.

[38]  C. Wahlestedt,et al.  Neuropeptide Y potentiates noradrenaline-evoked vasoconstriction: mode of action. , 1985, The Journal of pharmacology and experimental therapeutics.

[39]  W. Lautt Resistance or conductance for expression of arterial vascular tone. , 1989, Microvascular research.

[40]  K. Rudolf,et al.  Pharmacological characterization of the selective nonpeptide neuropeptide Y Y1 receptor antagonist BIBP 3226. , 1995, The Journal of pharmacology and experimental therapeutics.

[41]  R. Malmström,et al.  Autoinhibitory function of the sympathetic prejunctional neuropeptide Y Y(2) receptor evidenced by BIIE0246. , 2002, European journal of pharmacology.

[42]  D. Jackson,et al.  Neuropeptide Y bioavailability is suppressed in the hindlimb of female Sprague‐Dawley rats , 2005, The Journal of physiology.

[43]  T. Hökfelt,et al.  Neuropeptide Y: presence in perivascular noradrenergic neurons and vasoconstrictor effects on skeletal muscle blood vessels in experimental animals and man , 1987, Regulatory Peptides.

[44]  J. Angus,et al.  The alpha adrenoceptors on endothelial cells. , 1986, Federation proceedings.

[45]  G. Liu,et al.  The signal transduction pathway causing the synergistic hypertrophic effects of neuropeptide Y and norepinephrine on primary cardiomyocyte , 2001, Neuropeptides.

[46]  P. Clifford,et al.  The Paradox of Sympathetic Vasoconstriction in Exercising Skeletal Muscle , 2001, Exercise and sport sciences reviews.

[47]  R. Quirion,et al.  Comparative characterization and autoradiographic distribution of neuropeptide Y receptor subtypes in the rat brain , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[48]  Seymour Reichlin,et al.  Handbook of experimental pharmacology , 1984 .

[49]  Z. Żukowska-Grójec,et al.  Role of neuropeptide Y (NPY) in cardiovascular responses to stress , 1988, Synapse.

[50]  Z. Żukowska-Grójec,et al.  Neuropeptide Y: an adrenergic cotransmitter, vasoconstrictor, and a nerve-derived vascular growth factor. , 1998, Advances in pharmacology.

[51]  R. Malmström Existence of both neuropeptide Y, Y1 and Y2 receptors in pig spleen: evidence using subtype-selective antagonists in vivo. , 2001, Life sciences.

[52]  V. Miller,et al.  Alpha 2-adrenoceptors and endothelium-derived relaxing factor. , 1989, The American journal of medicine.

[53]  H. Herzog,et al.  The ability of neuropeptide Y to mediate responses in the murine cutaneous microvasculature: an analysis of the contribution of Y1 and Y2 receptors , 2003, British journal of pharmacology.

[54]  P. Clifford,et al.  Sympathetic restraint of muscle blood flow at the onset of dynamic exercise. , 2002, Journal of applied physiology.

[55]  F. Sundler,et al.  FP, PYY, and NPY: Occurrence and Distribution in the Periphery , 1993 .

[56]  C. Adreani,et al.  Muscle reflex stimulates sympathetic postganglionic efferents innervating triceps surae muscles of cats. , 1996, The American journal of physiology.

[57]  J. Kitlinska,et al.  Mitogenic actions of neuropeptide Y in vascular smooth muscle cells: synergetic interactions with the beta-adrenergic system. , 2003, Canadian journal of physiology and pharmacology.

[58]  P. Clifford,et al.  α-Adrenergic vasoconstriction in active skeletal muscles during dynamic exercise. , 1999, American journal of physiology. Heart and circulatory physiology.

[59]  P. Clifford,et al.  Vasoconstriction in active skeletal muscles: a potential role for P2X purinergic receptors? , 2003, Journal of applied physiology.

[60]  C. Wahlestedt,et al.  Origin and Actions of Neuropeptide Y in the Cardiovascular System , 1993 .

[61]  V. Miller,et al.  Alpha2-adrenoceptors and endothelium-derived relaxing factor , 1989 .

[62]  J. Mitchell,et al.  Functional Sympatholysis During Muscular Activity: OBSERVATIONS ON INFLUENCE OF CAROTID SINUS ON OXYGEN UPTAKE , 1962, Circulation research.

[63]  J. Johnson,et al.  Nonnoradrenergic mechanism of reflex cutaneous vasoconstriction in men. , 2001, American journal of physiology. Heart and circulatory physiology.

[64]  D. O'Leary,et al.  Integrative control of the skeletal muscle microcirculation in the maintenance of arterial pressure during exercise. , 2004, Journal of applied physiology.

[65]  D. Erlinge,et al.  Forearm blood flow responses to neuropeptide Y, noradrenaline and adenosine 5'-triphosphate in hypertensive and normotensive subjects. , 2000, Blood pressure.

[66]  A. Ng,et al.  Age and gender influence muscle sympathetic nerve activity at rest in healthy humans. , 1993, Hypertension.

[67]  D. Erlinge,et al.  Contractile effects of neuropeptide Y in human subcutaneous resistance arteries are mediated by Y1 receptors. , 1996, Journal of cardiovascular pharmacology.

[68]  W. Rascher,et al.  Neuropeptide Y: a possible role in hypertension? , 1995, Journal of hypertension.

[69]  N. Charkoudian,et al.  Sympathetic nonnoradrenergic cutaneous vasoconstriction in women is associated with reproductive hormone status. , 2002, American journal of physiology. Heart and circulatory physiology.

[70]  D. Erlinge,et al.  In vivo receptor characterization of neuropeptide Y‐induced effects in consecutive vascular sections of cat skeletal muscle , 1997, British journal of pharmacology.

[71]  P. Hjemdahl,et al.  Co-release of neuropeptide Y and catecholamines during physical exercise in man. , 1985, Biochemical and biophysical research communications.

[72]  T. Pedrazzini,et al.  Cardiovascular response, feeding behavior and locomotor activity in mice lacking the NPY Y1 receptor , 1998, Nature Medicine.

[73]  Long Dm,et al.  Carotid artery loop for repeated catheterization of the left ventricle in dogs. , 1971 .

[74]  G. Grassi,et al.  Sympathetic activation in the pathogenesis of hypertension and progression of organ damage. , 1999, Hypertension.

[75]  J. Angus,et al.  Endothelium-dependent relaxation of coronary arteries by noradrenaline and serotonin , 1983, Nature.

[76]  Y. Shigeri,et al.  Neuropeptide Y stimulates DNA synthesis in vascular smooth muscle cells , 1993, Neuroscience Letters.

[77]  D. Reis,et al.  Neuropeptide Y Receptor Subtypes, Y1 and Y2 , 1990, Annals of the New York Academy of Sciences.

[78]  P. Clifford,et al.  Effect of dynamic exercise on renal sympathetic nerve activity in conscious rabbits. , 1993, Journal of applied physiology.

[79]  John M. Johnson,et al.  Sympathetic, sensory, and nonneuronal contributions to the cutaneous vasoconstrictor response to local cooling. , 2005, American journal of physiology. Heart and circulatory physiology.

[80]  G. Hodges,et al.  The involvement of norepinephrine, neuropeptide Y, and nitric oxide in the cutaneous vasodilator response to local heating in humans. , 2008, Journal of applied physiology.

[81]  W. Haefeli,et al.  Human neuropeptide Y potentiates α1-adrenergic blood pressure responses in vivo. , 1998, American journal of physiology. Heart and circulatory physiology.

[82]  T. Branchek,et al.  Expression Cloning and Pharmacological Characterization of a Human Hippocampal Neuropeptide Y/Peptide YY Y2 Receptor Subtype (*) , 1995, The Journal of Biological Chemistry.

[83]  D. Kimmerly,et al.  Gender affects sympathetic and hemodynamic response to postural stress. , 2001, American journal of physiology. Heart and circulatory physiology.

[84]  M. Joyner,et al.  α1- and α2-adrenergic vasoconstriction is blunted in contracting human muscle , 2003 .

[85]  Daniel Grandt,et al.  Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV , 1993, Regulatory Peptides.

[86]  V. Mutt,et al.  Neuropeptide Y—a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide , 1982, Nature.

[87]  B. Saltin,et al.  Maximal perfusion of skeletal muscle in man. , 1985, The Journal of physiology.

[88]  M. Statnick,et al.  Characterization of the neuropeptide Y5 receptor in the human hypothalamus: a lack of correlation between Y5 mRNA levels and binding sites , 1998, Brain Research.

[89]  J. Lundberg,et al.  Pancreatic polypeptide family (APP, BPP, NPY and PYY) in relation to sympathetic vasoconstriction resistant to alpha-adrenoceptor blockade. , 1982, Acta physiologica Scandinavica.

[90]  W. De Potter,et al.  Noradrenaline Storing Vesicles in Sympathetic Neurons and Their Putative Role in Neurotransmitter Release: An Historical Overview of Controversial Issues , 1997, Neurochemical Research.

[91]  P. De Camilli,et al.  Pathways to regulated exocytosis in neurons. , 1990, Annual review of physiology.

[92]  P. Hjemdahl,et al.  Plasma neuropeptide Y-like immunoreactivity and catecholamines during various degrees of sympathetic activation in man. , 2008, Clinical physiology.

[93]  D. Seals,et al.  Age-associated arterial wall thickening is related to elevations in sympathetic activity in healthy humans. , 2000, American journal of physiology. Heart and circulatory physiology.

[94]  D. Jackson,et al.  Gender‐modulated endogenous baseline neuropeptide Y Y1‐receptor activation in the hindlimb of Sprague‐Dawley rats , 2005, The Journal of physiology.

[95]  A. Pessina,et al.  Sympathetic drive and vascular damage in hypertension and atherosclerosis. , 1991, Hypertension.

[96]  G. Schnorrenberg,et al.  BIIE0246: a selective and high affinity neuropeptide Y Y(2) receptor antagonist. , 1999, European journal of pharmacology.

[97]  L. Rowell Human Cardiovascular Control , 1993 .

[98]  E. Coen,et al.  Evidence against differential release of noradrenaline, neuropeptide Y, and dopamine‐β‐hydroxylase from adrenergic nerves in the isolated perfused sheep spleen , 1995, Synapse.

[99]  W. E. Glover INCREASED SENSITIVITY OF RABBIT EAR ARTERY TO NORADRENALINE FOLLOWING PERIVASCULAR NERVE STIMULATION MAY BE A RESPONSE TO NEUROPEPTIDE Y RELEASED AS COTRANSMITTER , 1985, Clinical and experimental pharmacology & physiology.

[100]  G. Jennings,et al.  Adverse consequences of high sympathetic nervous activity in the failing human heart. , 1995, Journal of the American College of Cardiology.

[101]  T. Glenn,et al.  Vascular responses to neuropeptide Y are greater in female than male rats , 1996, Naunyn-Schmiedeberg's Archives of Pharmacology.

[102]  T. Hedner,et al.  Does the neuropeptide Y Y1 receptor contribute to blood pressure control in the spontaneously hypertensive rat? , 1997, Journal of hypertension.

[103]  M. Michel,et al.  Gender and hypertension interact to regulate neuropeptide Y receptor responsiveness , 2000, Naunyn-Schmiedeberg's Archives of Pharmacology.

[104]  S. Sabol,et al.  Rat neuropeptide Y precursor gene expression. mRNA structure, tissue distribution, and regulation by glucocorticoids, cyclic AMP, and phorbol ester. , 1988, The Journal of biological chemistry.

[105]  A. Beck‐Sickinger,et al.  The first highly potent and selective non-peptide neuropeptide Y Y1 receptor antagonist: BIBP3226. , 1994, European journal of pharmacology.

[106]  J. Huidobro-Toro,et al.  Neuropeptide Y-induced pressor responses: activation of a non-adrenergic mechanism, potentiation by reserpine and blockade by nifedipine. , 1985, European journal of pharmacology.

[107]  L. Edvinsson,et al.  Neuropeptide Y Y1 and neuropeptide Y Y2 receptors in human cardiovascular tissues , 2002, Peptides.

[108]  G. Fisone,et al.  Regulation of the release of coexisting neurotransmitters. , 1988, Annual review of pharmacology and toxicology.

[109]  J. Lundberg Pharmacology of cotransmission in the autonomic nervous system: integrative aspects on amines, neuropeptides, adenosine triphosphate, amino acids and nitric oxide. , 1996, Pharmacological reviews.

[110]  G. Grassi,et al.  Cardiovascular risk and adrenergic overdrive in the metabolic syndrome. , 2007, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[111]  A. Franco‐Cereceda,et al.  Differential release of classical transmitters and peptides. , 1994, Advances in second messenger and phosphoprotein research.

[112]  F. Yamazaki,et al.  Rate dependency and role of nitric oxide in the vascular response to direct cooling in human skin. , 2006, Journal of applied physiology.

[113]  K. Matsukawa,et al.  Anesthetic effects on tonic and reflex renal sympathetic nerve activity in awake cats. , 1989, The American journal of physiology.

[114]  G. Hodges,et al.  The involvement of nitric oxide in the cutaneous vasoconstrictor response to local cooling in humans , 2006, The Journal of physiology.

[115]  J. Lundberg,et al.  Neuropeptide Y (NPY): enhancement of blood pressure increase upon alpha-adrenoceptor activation and direct pressor effects in pithed rats. , 1985, European journal of pharmacology.

[116]  M. Joyner,et al.  Is sympathetic neural vasoconstriction blunted in the vascular bed of exercising human muscle? , 2002, The Journal of physiology.

[117]  E. Potter,et al.  Effects of a selective neuropeptide Y Y2 receptor antagonist, BIIE0246, on Y2 receptors at peripheral neuroeffector junctions , 2001, British journal of pharmacology.

[118]  C. Wahlestedt,et al.  Neuropeptide Y co-exists and co-operates with noradrenaline in perivascular nerve fibers , 1984, Regulatory Peptides.

[119]  P. Clifford,et al.  Do P2X purinergic receptors regulate skeletal muscle blood flow during exercise? , 2004, American journal of physiology. Heart and circulatory physiology.

[120]  G. Burnstock,et al.  Direct evidence for concomitant release of noradrenaline, adenosine 5'-triphosphate and neuropeptide Y from sympathetic nerve supplying the guinea-pig vas deferens. , 1988, Journal of the autonomic nervous system.

[121]  H. Matsubayashi,et al.  Compensatory vasoconstrictor effects of sodium pentobarbital on the hindquarters of conscious normotensive control and lumbar-sympathectomized Wistar rats , 2000, Autonomic Neuroscience.

[122]  Lydia E. Kuo,et al.  Stress, NPY and vascular remodeling: Implications for stress-related diseases , 2007, Peptides.

[123]  W. Rascher,et al.  Regulation of NPY/NPY Y1 receptor/G protein system in rat brain cortex. , 1995, The American journal of physiology.

[124]  J. Dixon,et al.  Cloning, characterization, and DNA sequence of a human cDNA encoding neuropeptide tyrosine. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[125]  S. Bloom,et al.  Neuropeptide Y and drug development , 1997 .

[126]  J. Chalmers,et al.  Increases in plasma neuropeptide Y concentrations during sympathetic activation in man. , 1986, Journal of the autonomic nervous system.

[127]  G. Burnstock,et al.  The contributions of noradrenaline and ATP to the responses of the rabbit central ear artery to sympathetic nerve stimulation depend on the parameters of stimulation. , 1986, European journal of pharmacology.

[128]  R. Malmström Neuropeptide Y Y1 receptor mechanisms in sympathetic vascular control. , 1997, Acta physiologica Scandinavica. Supplementum.

[129]  A. Schoups,et al.  Noradrenergic neurons release both noradrenaline and neuropeptide Y from a single pool: The large dense cored vesicles , 1997, Synapse.

[130]  Caitlin Thompson,et al.  Altered neurotransmitter control of reflex vasoconstriction in aged human skin , 2004, The Journal of physiology.

[131]  J. L. Morris Selective constriction of small cutaneous arteries by NPY matches distribution of NPY in sympathetic axons , 1994, Regulatory Peptides.

[132]  C. S. Gal,et al.  The cloned guinea pig neuropeptide Y receptor Y1 conforms to other mammalian Y1 receptors , 1999, Peptides.

[133]  Jia-Yi Li,et al.  Neuropeptide Y2 receptors are involved in enhanced neurogenic vasoconstriction in spontaneously hypertensive rats , 2006, British journal of pharmacology.

[134]  R. Kelly Storage and release of neurotransmitters , 1993, Cell.

[135]  D L Kellogg,et al.  Cutaneous active vasodilation in humans is mediated by cholinergic nerve cotransmission. , 1995, Circulation research.

[136]  M. Lapiński,et al.  Plasma neuropeptide Y and catecholamines in women and men with essential hypertension. , 1995, Blood pressure.

[137]  P. Hjemdahl,et al.  Possible involvement of neuropeptide Y in sympathetic vascular control of canine skeletal muscle. , 1988, Acta physiologica Scandinavica.

[138]  John M. Johnson,et al.  Neuropeptide Y antagonism reduces reflex cutaneous vasoconstriction in humans. , 2004, American journal of physiology. Heart and circulatory physiology.

[139]  A. Mark,et al.  Central command increases sympathetic nerve activity during spontaneous locomotion in cats. , 1991, Circulation research.

[140]  A. Franco‐Cereceda,et al.  Neuropeptide Y Y1 receptors in vascular pharmacology. , 1998, European journal of pharmacology.

[141]  R. Armstrong,et al.  Progressive elevations in muscle blood flow during prolonged exercise in swine. , 1987, Journal of applied physiology.

[142]  T. Hökfelt,et al.  Characterization and molecular cloning of vascular neuropeptide Y receptor subtypes in pig and dog , 1998, Regulatory Peptides.

[143]  A. Franco‐Cereceda,et al.  Neuropeptide Y and Sympathetic Neurotransmission a , 1990, Annals of the New York Academy of Sciences.

[144]  T. Hedner,et al.  Neuropeptide Y potentiates noradrenaline-induced contraction through the neuropeptide Y Y1 receptor. , 1996, European journal of pharmacology.

[145]  D. Jackson,et al.  Y1- and α1-receptor control of basal hindlimb vascular tone , 2004 .

[146]  C. D. Johnson,et al.  Effects of varying impulse number on cotransmitter contributions to sympathetic vasoconstriction in rat tail artery. , 2003, American journal of physiology. Heart and circulatory physiology.

[147]  P. Clifford,et al.  Skeletal muscle vasodilation at the onset of exercise. , 1998, Journal of applied physiology.